In reply - Sensitivity of [18F]-fluorodeoxyglucosee positron emission tomography in patients with active myelopathy

B. Mark Keegan; Eoin P. Flanagan

doi:10.1016/j.mayocp.2014.03.009

In reply - Sensitivity of [¹⁸F]-fluorodeoxyglucosee positron emission tomography in patients with active myelopathy

B. Mark Keegan, Eoin P. Flanagan

Neurology

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	859
Number of pages	1
Journal	Mayo Clinic proceedings
Volume	89
Issue number	6
DOIs	https://doi.org/10.1016/j.mayocp.2014.03.009
State	Published - Jun 2014

ASJC Scopus subject areas

General Medicine

Access to Document

10.1016/j.mayocp.2014.03.009

Cite this

@article{4c4d2c6a3f144031ad05a1312b3df053,

title = "In reply - Sensitivity of [18F]-fluorodeoxyglucosee positron emission tomography in patients with active myelopathy",

author = "Keegan, {B. Mark} and Flanagan, {Eoin P.}",

year = "2014",

month = jun,

doi = "10.1016/j.mayocp.2014.03.009",

language = "English (US)",

volume = "89",

pages = "859",

journal = "Mayo Clinic proceedings",

issn = "0025-6196",

publisher = "Elsevier Science",

number = "6",

}

TY - JOUR

T1 - In reply - Sensitivity of [18F]-fluorodeoxyglucosee positron emission tomography in patients with active myelopathy

AU - Keegan, B. Mark

AU - Flanagan, Eoin P.

PY - 2014/6

Y1 - 2014/6

UR - http://www.scopus.com/inward/record.url?scp=84904659700&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904659700&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2014.03.009

DO - 10.1016/j.mayocp.2014.03.009

M3 - Letter

C2 - 24943702

AN - SCOPUS:84904659700

SN - 0025-6196

VL - 89

SP - 859

JO - Mayo Clinic proceedings

JF - Mayo Clinic proceedings

IS - 6

ER -

In reply - Sensitivity of [18F]-fluorodeoxyglucosee positron emission tomography in patients with active myelopathy

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this

In reply - Sensitivity of [¹⁸F]-fluorodeoxyglucosee positron emission tomography in patients with active myelopathy